Nifekalant Hydrochloride and Amiodarone Hydrochloride Result in Similar Improvements for 24-Hour Survival in Cardiopulmonary Arrest Patients: The SOS-KANTO 2012 Study

Journal of Cardiovascular Pharmacology
Mari AminoSOS-KANTO 2012 Study Group

Abstract

Amiodarone (AMD), nifekalant (NIF), and lidocaine (LID) hydrochlorides are widely used for ventricular tachycardia/fibrillation (VT/VF). This study retrospectively investigated the NIF potency and the differential effects of 2 initial AMD doses (≤150 mg or 300 mg) in the Japanese SOS-KANTO 2012 study population. From 16,164 out-of-hospital cardiac arrest cases, 500 adult patients using a single antiarrhythmic drug for shock-resistant VT/VF were enrolled and categorized into 4 groups (73 LID, 47 NIF, 173 AMD-≤150, and 207 AMD-300). Multivariate analyses evaluated the outcomes of NIF, AMD-≤150, or AMD-300 groups versus LID group. Odds ratios (ORs) for survival to admission were 3.21 [95% confidence interval (CI): 1.38-7.44, P < 0.01] in NIF and 3.09 (95% CI: 1.55-6.16, P < 0.01) in AMD-≤150 groups and significantly higher than those of the LID group. However, the OR was 1.78 (95% CI: 0.90-3.51, P = 0.10) in AMD-300 group and was not significant than LID group. ORs for 24-hour survival were 6.68 in NIF, 4.86 in AMD-≤150, and 2.97 in AMD-300, being significantly higher in these groups. NIF and AMD result in similar improvements for 24-hour survival in cardiopulmonary arrest patients, and this suggest the necessity of a randomized c...Continue Reading

References

Nov 15, 1986·The American Journal of Cardiology·E P Veltri, P R Reid
Dec 1, 1996·Journal of Clinical Epidemiology·P PeduzziA R Feinstein
Sep 16, 1999·The New England Journal of Medicine·P J KudenchukT Walsh
Nov 24, 1999·The American Journal of Cardiology·I KodamaJ Toyama
Sep 7, 2000·Cardiovascular Research·M R BoyettI Kodama
Mar 22, 2002·The New England Journal of Medicine·Paul DorianAiala Barr
Mar 28, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Yoshio TaharaSatoshi Umemura
Feb 3, 2009·Resuscitation·Toshikazu AbeUNKNOWN SOS-KANTO study group
Feb 6, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·UNKNOWN SOS-KANTO study group
Jun 6, 2009·Journal of Pharmacological Sciences·Atsushi TamuraHaruaki Nakaya
Nov 17, 2009·Resuscitation·Tsuyoshi ShigaUNKNOWN Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant (RELIEF) Study Investigators
Mar 20, 2010·The New England Journal of Medicine·Tetsuhisa KitamuraUNKNOWN Implementation Working Group for the All-Japan Utstein Registry of the Fire and Disaster Management Agency
Oct 22, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Ken Nagao
Jan 15, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·UNKNOWN Survey of Survivors After Out-of-hospital Cardiac Arrest in KANTO Area, Japan (SOS-KANTO) Study Group
Jun 7, 2011·The American Journal of Emergency Medicine·UNKNOWN SOS-KANTO study group
Mar 23, 2012·JAMA : the Journal of the American Medical Association·Akihito HagiharaShogo Miyazaki
Jul 21, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Taketomo SogaUNKNOWN J-PULSE-Hypo Investigators
Jan 17, 2013·JAMA : the Journal of the American Medical Association·Kohei HasegawaDavid F M Brown
Apr 26, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Akihiro ShirakabeKyoichi Mizuno
Jan 28, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·Yoshihide MitaniNaokata Sumitomo

❮ Previous
Next ❯

Citations

Oct 14, 2017·Acta Cardiologica·George Karlis, Sevasti Afantenou
Mar 24, 2016·Journal of Cardiovascular Pharmacology·Mari AminoUNKNOWN SOS-KANTO 2012 study group
Mar 23, 2017·Critical Care : the Official Journal of the Critical Care Forum·Takashi TagamiHiroyuki Yokota

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.